AAVANTGARDE
"AAVANTGARDE" is a word mark owned by AAVantgarde Bio Srl, filed at the USPTO on January 8, 2024. It is registered and covers classes 5, 10, 40, 42 and 44.
- Status
- Registered
- Since February 17, 2026
- Filed
- January 8, 2024
- Registered
- February 17, 2026
- Priority date
- January 8, 2024
- Claimed from United Kingdom
- Application no.
- 98346994
- Registration no.
- 8140404
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 5 classes
Who owns AAVANTGARDE
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
AAVantgarde Bio Srl
Milan, Italy
Representative
Scott J. Major
Millen White Zelano & Branigan, PC
What the mark covers
The products and services AAVANTGARDE is filed for, grouped by Nice class.
Medical and veterinary preparations for therapeutic purposes, namely, pharmaceutical preparations for treatment of genetic diseases; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceuticals for the delivery of genes to cells, all for medical purposes; chemical preparations for use in medical science, namely, in gene therapy and cell therapy; biologic preparations for medical purposes, namely, for use in gene therapy and cell therapy; biologic preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for use in treatment of genetically based diseases and disorders; gene therapy preparations for medical purposes, namely, adeno-associated viral preparations; pharmaceutical preparations in the nature of adeno-associated viral gene therapy preparations; pharmaceutical preparations and substances for the treatment of ocular and otological disorders; biotechnological preparations for the treatment of ocular and otological disorders; pharmaceutical preparations for gene therapy and cell therapy for the treatment of ocular and otological disorders; genetic medicines for the treatment of ocular and otological disorders; biologic preparations for use in the treatment of ophthalmological diseases and disorders; biologic preparations for use in the treatment of blinding and deafness diseases and disorders; biologic preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; gene therapy preparations for use in the treatment of ophthalmological diseases and disorders; gene therapy preparations for use in the treatment of blinding and deafness diseases and disorders; gene therapy preparations for use in the treatment of complement pathway-related or complement pathway-mediated diseases or disorders; adhesive pads for medical and surgical use
Medical and surgical apparatus and instruments for use in gene therapy and cell therapy; medical devices for use in gene therapy and cell therapy; apparatus and instruments for the administration of gene therapy products; ophthalmic surgery devices and instruments; veterinary apparatus and instruments for use in gene therapy and cell therapy; cannulae for use in ophthalmic procedures; needles for surgical and medical purposes; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof; apparatus and instruments for performing eye surgery; ophthalmic surgery devices and instruments for controlled sub-retinal delivery of pharmaceutical, biologic, cell therapy, and gene therapy products via the suprachoroidal space; medical and veterinary apparatus and instruments for controlled drug delivery during ophthalmic surgery; ophthalmic apparatus and instruments, namely, surgical instruments for use in delivery and administration of fluid, biologics and pharmaceuticals during ophthalmic procedures, including surgery; apparatus and instruments for treating the eye, namely, cannulas and needles for obtaining sub-retinal access for delivery of pharmaceutical and biologic preparations in the sub-retinal space; apparatus and instruments for treating the eye, namely, cannulas and needles for delivery of pharmaceutical and biologic preparations in the suprachoroidal space; apparatus and instruments for dispensing or delivering preparations into the eye or structures thereof, namely, devices for sub-retinal delivery via suprachoroidal space of pharmaceutical and biologic, cell therapy and gene therapy products; with none of the foregoing goods for the purpose of bowel management or collection of bodily waste
Custom manufacturing of pharmaceuticals and pharmaceutical processing; custom manufacturing of biotechnological pharmaceuticals and biopharmaceuticals and processing of biotechnological pharmaceuticals and biopharmaceuticals; biomanufacturing for others, namely, manufacturing of viral vectors using biological organisms in the manufacturing process; custom manufacturing of pharmaceuticals for gene therapy; pharmaceutical formulation being custom pharmaceutical manufacturing; information, advice and consultancy services relating to the aforementioned services
Scientific and technological services and research or design relating thereto, namely, scientific research in the fields of gene therapy and cell therapy; industrial analysis and research services in the fields of gene therapy and cell therapy; biological and medical product research and development; preclinical and clinical research and development in the fields of gene therapy and cell therapy; gene therapy research; genetic engineering, gene editing, namely, the modification of genetic material in a living organism; genetic medicine, gene therapy and genome editing research, development, analytics, clinical trials and consultancy relating thereto; biochemical assay development and performance, namely, monitoring of patients prior and subsequent to gene therapy; diagnostics development and performance, namely, monitoring of patients prior and subsequent to gene therapy; biomarker identification, namely, detection and measurement of biological properties or molecules in the body; manufacturing analytics and manufacturing process design, development and optimisation; scientific research and development services and clinical trials services in relation to pharmaceutical preparations and substances for the treatment of disorders relating to the eye and ear, biotechnological preparations for the treatment of disorders relating to the eye and ear, preparations for gene therapy and cell therapy for the treatment of disorders relating to the eye and ear and genetic medicines for the treatment of disorders relating to the eye and ear; information, advice and consultancy services relating to the aforementioned services
Medical services; medical services in the field of genetic or inherited or non-infectious diseases or disorders; medical services in the field of gene therapy or genetic medicine; medical services in the field of gene therapy for ophthalmological diseases and disorders, blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, renal and kidney disorders, hepatological disorders, or nervous system disorders; medical services, namely, gene and nucleic acid delivery and modification for therapeutic purposes in the fields of gene therapy and cell therapy; medical services, namely, gene therapy design and delivery in the fields of gene therapy and cell therapy; medical advisory services relating to gene therapy; provision of a website providing educational information relating to medical services, namely, gene therapy or genetic medicine; advisory, consultancy and information services relating to the treatment, relief and/or prevention of eye and ear disease, single gene disorders, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders; information, advice and consultancy services relating to the aforementioned services
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of registration confirmation emailed
- Registered-principal register
- 1(b) basis deleted; proceed to registration
- Case assigned to intent to use paralegal
- Notice of allowance cancelled
- Teas delete 1(b) basis received
- Noa e-mailed - sou required from applicant
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
10 earlier steps on the official record.
About AAVANTGARDE
Who owns the trademark "AAVANTGARDE"?
The USPTO trademark "AAVANTGARDE" (application 98346994) is owned by AAVantgarde Bio Srl.
What is the status of "AAVANTGARDE"?
Its status at the USPTO is: registered.
When was "AAVANTGARDE" registered?
It was registered on February 17, 2026.
Get this data via the API
Everything on this page comes from the Signa API. Pull AAVANTGARDE and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2c7a-c413-75e9-b110-2d407b7536a8
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2c7a-c413-75e9-b110-2d407b7536a8",
"object": "trademark",
"mark_text": "AAVANTGARDE",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "98346994",
"filing_date": "2024-01-08",
"nice_classes": [
5,
10,
40,
42,
44
],
"owners": [
{
"name": "AAVantgarde Bio Srl",
"entity_id": "ent_019ebb95-9481-7158-86af-d1dda2395144"
}
]
}